Literature DB >> 31862245

Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis.

Catherine de Martel1, Damien Georges2, Freddie Bray3, Jacques Ferlay3, Gary M Clifford2.   

Abstract

BACKGROUND: Infectious pathogens are strong and modifiable causes of cancer. The aim of this study was to improve estimates of the global and regional burden of infection-attributable cancers to inform research priorities and facilitate prevention efforts.
METHODS: We used the GLOBOCAN 2018 database of cancer incidence and mortality rates and estimated the attributable fractions and global incidence for specific anatomical cancer sites, subsites, or histological subtypes known to be associated with ten infectious pathogens classified as human carcinogens. We calculated absolute numbers and age-standardised incidence rates (ASIR) of infection-attributable cancers at the country level. Estimates were stratified for sex, age group, and country, and were aggregated according to geographical regions and World Bank income groups.
FINDINGS: We found that, for 2018, an estimated 2·2 million infection-attributable cancer cases were diagnosed worldwide, corresponding to an infection-attributable ASIR of 25·0 cases per 100 000 person-years. Primary causes were Helicobacter pylori (810 000 cases, ASIR 8·7 cases per 100 000 person-years), human papillomavirus (690 000, 8·0), hepatitis B virus (360 000, 4·1) and hepatitis C virus (160 000, 1·7). Infection-attributable ASIR was highest in eastern Asia (37·9 cases per 100 000 person-years) and sub-Saharan Africa (33·1), and lowest in northern Europe (13·6) and western Asia (13·8). China accounted for a third of worldwide cancer cases attributable to infection, driven by high ASIR of H pylori (15·6) and hepatitis B virus (11·7) infection. The cancer burden attributed to human papillomavirus showed the clearest relationship with country income level (from ASIR of 6·9 cases per 100 000 person-years in high-income countries to 16·1 in low-income countries).
INTERPRETATION: Infection-attributable cancer incidence, in addition to the absolute number of cases, allows for refined geographic analyses and identification of populations with a high infection-associated cancer burden. When cancer prevention is largely considered in a non-communicable disease context, there is a crucial need for resources directed towards cancer prevention programmes that target infection, particularly in high-risk populations. Such interventions can markedly reduce the increasing cancer burden and associated mortality. FUNDING: International Agency for Research on Cancer.
© 2020 International Agency for Research on Cancer; licensee Elsevier. This is an Open Access article published under the CC BY-NC-ND 3.0 IGO license which permits users to download and share the article for non-commercial purposes, so long as the article is reproduced in the whole without changes, and provided the original source is properly cited. This article shall not be used or reproduced in association with the promotion of commercial products, services or any entity. There should be no suggestion that IARC endorses any specific organisation, products or services. The use of the IARC logo is not permitted. This notice should be preserved along with the article's original URL.

Entities:  

Mesh:

Year:  2019        PMID: 31862245     DOI: 10.1016/S2214-109X(19)30488-7

Source DB:  PubMed          Journal:  Lancet Glob Health        ISSN: 2214-109X            Impact factor:   26.763


  253 in total

Review 1.  Sex disparities matter in cancer development and therapy.

Authors:  Sue Haupt; Franco Caramia; Sabra L Klein; Joshua B Rubin; Ygal Haupt
Journal:  Nat Rev Cancer       Date:  2021-04-20       Impact factor: 60.716

Review 2.  Circular RNAs in Immune Response and Viral Infection.

Authors:  Lichong Yan; Y Grace Chen
Journal:  Trends Biochem Sci       Date:  2020-09-06       Impact factor: 13.807

Review 3.  [Prevention of HPV-induced diseases by prophylactic vaccination].

Authors:  Ulrike Wieland; Alexander Kreuter
Journal:  Hautarzt       Date:  2020-12-18       Impact factor: 0.751

4.  Ornithine decarboxylase (ODC1) gene variant (rs2302615) is associated with gastric cancer independently of Helicobacter pylori CagA serostatus.

Authors:  Anna K Miller; Gloria Tavera; Scott M Williams; Douglas R Morgan; Ricardo L Dominguez; M Constanza Camargo; Tim Waterboer; Keith T Wilson
Journal:  Oncogene       Date:  2021-08-10       Impact factor: 9.867

5.  Short- and long-range cis interactions between integrated HPV genomes and cellular chromatin dysregulate host gene expression in early cervical carcinogenesis.

Authors:  Ian J Groves; Emma L A Drane; Marco Michalski; Jack M Monahan; Cinzia G Scarpini; Stephen P Smith; Giovanni Bussotti; Csilla Várnai; Stefan Schoenfelder; Peter Fraser; Anton J Enright; Nicholas Coleman
Journal:  PLoS Pathog       Date:  2021-08-25       Impact factor: 6.823

6.  Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.

Authors:  Anna Godi; Dolcibella Boampong; Busayo Elegunde; Kavita Panwar; Maxime Fleury; Shaowei Li; Qinjian Zhao; Ningshao Xia; Neil D Christensen; Simon Beddows
Journal:  J Virol       Date:  2020-11-23       Impact factor: 5.103

Review 7.  Planning for tomorrow: global cancer incidence and the role of prevention 2020-2070.

Authors:  Isabelle Soerjomataram; Freddie Bray
Journal:  Nat Rev Clin Oncol       Date:  2021-06-02       Impact factor: 66.675

Review 8.  Turning Discoveries into Treatments: Immunology in Africa.

Authors:  Faith H A Osier; Henry C Mwandumba; Clive M Gray
Journal:  Trends Immunol       Date:  2020-11-04       Impact factor: 16.687

9.  The association of Candida and antifungal therapy with pro-inflammatory cytokines in oral leukoplakia.

Authors:  Shalini R Gupta; Nidhi Gupta; Alpana Sharma; Immaculata Xess; Gagandeep Singh; Kalaivani Mani
Journal:  Clin Oral Investig       Date:  2021-04-04       Impact factor: 3.573

10.  The Colombian Chemoprevention Trial: 20-Year Follow-Up of a Cohort of Patients With Gastric Precancerous Lesions.

Authors:  M Blanca Piazuelo; Luis E Bravo; Robertino M Mera; M Constanza Camargo; Juan C Bravo; Alberto G Delgado; M Kay Washington; Alicia Rosero; Luz S Garcia; Jose L Realpe; Sandra P Cifuentes; Douglas R Morgan; Richard M Peek; Pelayo Correa; Keith T Wilson
Journal:  Gastroenterology       Date:  2020-11-18       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.